ERBB2 and breast cancer: Additionally, understanding the shifting distribution of each molecular subtype, as evidenced by Chuaychai et al.'s research on the rising prevalence of HER2+ tumors from 2009 to 2018 [49], and in the SEER study between 2010 to 2016 [29], can also aid in alleviating the burden of BC.